

Wednesday, December 2, 2009

**Washington Marriott Wardman Park
Washington, DC**

Medical Countermeasures: From the Bench to the Bloodstream

9:00 -10:30
Marriott
Salons II & III



HHS / AMA JOINT SESSION

**HHS Public Health Emergency Medical Countermeasures Enterprise
Stakeholders Workshop 2009**

and

American Medical Association

**Third National Congress on Health System Readiness:
Disaster Medicine and Public Health Preparedness in the 21st Century**



Opening Remarks

Secretary Kathleen Sebelius

U.S. Department of Health and Human Services



Gerald W. Parker, DVM, PhD, MS

Principal Deputy Assistant Secretary

Office of Preparedness and Response

U.S. Department of Health and Human Services



Alexander Garza, MD, MPH

Assistant Secretary for Health Affairs and Chief Medical Officer

U.S. Department of Homeland Security



Cecil B. Wilson, MD

President-Elect

American Medical Association



With all this preparedness, what have we forgotten?

Frederick M. Burkle, Jr., MD, MPH, DTM, FAAP, FACEP

Senior Public Policy Scholar, Woodrow Wilson International Center for Scholars

Senior Fellow, Harvard Humanitarian Initiative



*This icon indicates sessions that will be webcast live on December 2 and 3
and archived on www.MedicalCountermeasures.gov in January 2010.*

10:30 – 10:45 **Break in the Marriott Salon Lobby**

10:45 – 11:15
Marriott
Salons II & III



Moderator: Robin A. Robinson, PhD
Deputy Assistant Secretary, Office of Preparedness and Response
Director, Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services

HHS / AMA JOINT SESSION

PANEL: Environmental Monitoring and Human Health Surveillance

Early Detection

Robert R. Hooks

Deputy Assistant Secretary for Weapons of Mass Destruction and Biodefense
Office of Health Affairs
U.S. Department of Homeland Security

Human Health Surveillance and Public Health Biometrics

Daniel Sosin, MD, MPH, FACP

Captain, U.S. Public Health Service
Acting Director, Coordinating Office for Terrorism Preparedness and Emergency Response
Centers for Disease Control and Prevention
U.S. Department of Health and Human Services

11:15 – 11:45
Marriott
Salons II & III



HHS / AMA JOINT SESSION

PANEL: The Role of Public Health Laboratories and Clinical Diagnostics in Medical Countermeasure Preparedness

Laboratory Response Network

Lisa D. Rotz, MD, FIDSA

Director, Division of Bioterrorism Preparedness and Response
National Center for Preparedness, Detection, and Control of Infectious Diseases
Coordinating Center for Infectious Diseases, Centers for Disease Control and Prevention
U.S. Department of Health and Human Services

Association of Public Health Laboratories

Peter A. Shult, PhD

Director, Communicable Disease Division and Emergency Laboratory Response
Wisconsin State Laboratory of Hygiene

11:45 – 12:00
Marriott
Salons II & III



HHS / AMA JOINT SESSION

Medical Countermeasures in Federal Public Health Emergency Response Plans

Kevin Yeskey, MD

Deputy Assistant Secretary, Office of Preparedness and Response
Director, Office of Preparedness and Emergency Operations
U.S. Department of Health and Human Services

12:00 – 12:15
Marriott
Salons II & III



HHS / AMA JOINT SESSION

The Strategic National Stockpile of Public Health Emergency Medical Countermeasures

Greg Burel

Director, Division of Strategic National Stockpile
Coordinating Office for Terrorism Preparedness and Emergency Response
Centers for Disease Control and Prevention
U.S. Department of Health and Human Services

12:15 – 1:30 **Lunch On Your Own**

1:30 – 3:15	PHEMCE Stakeholders Breakout Discussion Sessions	
Virginia A	Priority-Setting for the Public Health Emergency Medical Countermeasures Enterprise	Host: Michael Mair, MPH Program Analyst; Policy, Planning, and Requirements Division Biomedical Advanced Research and Development Authority Office of the Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services
Virginia B	Regulatory Issues	Host: Debra A. Yeskey, PharmD Director, Regulatory and Quality Affairs Division Biomedical Advanced Research and Development Authority Office of the Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services
Virginia C	The Role of the Public in Public Health Preparedness	Hosts: Elin Gursky, ScD, MSc and Julie Hantman, MPH Policy, Planning, and Requirements Division Biomedical Advanced Research and Development Authority Office of the Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services
Maryland	Building and Sustaining Medical Countermeasure Industries for CBRN Threats and Pandemic Influenza	Host: Gerald R. Kovacs, PhD Director, CBRN Countermeasures Biomedical Advanced Research and Development Authority Office of the Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services
Wilson A	Community Preparedness for All-Hazards Response: Planning for Vulnerable Populations	Host: Todd Lennon, LCSW Lieutenant Commander, U.S. Public Health Service Team Lead for Operations Office for At-Risk Individuals, Behavioral Health, and Human Services Coordination Office of the Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services
Wilson B	National Health Security Strategy	Host: Matthew Minson, MD Senior Medical Officer for Strategic Initiatives Office of Policy, Strategic Planning, and Communications Office of the Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services
Wilson C	Performance Measures for Medical Countermeasure Distribution and Utilization in Public Health Emergency Response	Host: Stephanie M. Dulin, MBA Chief, Program Preparedness Branch Division of Strategic National Stockpile Coordinating Office for Terrorism Preparedness and Emergency Response Centers for Disease Control and Prevention U.S. Department of Health and Human Services

3:15 – 3:30

Break in the Marriott Salon Lobby

3:30 – 4:15

Marriott Salon II



Moderator: RADM Ann Knebel, RN, DNSc, FAAN

Deputy Director for Preparedness Planning
Office of Preparedness and Emergency Operations
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

**PANEL: State, Local, Tribal, and Territorial Medical Countermeasure
Dispensing – Best Practice Examples**

Dana Carey

Strategic National Stockpile Coordinator
Yolo County (California) Health Department

David L. Lakey, MD

Commissioner
Texas Department of State Health Services

Linda Scott, BSN, MA, CIC

Bioterrorism Hospital Preparedness Program Coordinator
Michigan Department of Community Health

4:15 – 5:00

Marriott Salon II



PANEL: Maximizing Resources in a Public Health Emergency Response

Medical Surge Capacity

Sally J. Phillips, RN, PhD

Director, Public Health Emergency Preparedness Research Program
Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services

The Hospital Preparedness Program

Gregg Pane, MD

Director, National Healthcare Preparedness Program
Office of Preparedness and Emergency Operations
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

Allocation of Scarce Resources

C. Norman Coleman, MD

Senior Investigator and Head, Experimental Therapeutics Section, Center for Cancer Research
Radiation Oncology Branch, National Cancer Institute, National Institutes of Health
Senior Medical Advisor and Chief of the CBRN Team
Office of Mass Casualty Planning, Office of Preparedness and Emergency Operations
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

5:00 – 6:00

**HHS / AMA JOINT EVENT
Reception and Poster Session – Exhibit Hall A**

Thursday, December 3, 2009

**Washington Marriott Wardman Park
Washington, DC**

Medical Countermeasures: From the Bench to the Bloodstream

**Thursday
December 3**

8:30 – 9:00
Marriott
Salons II & III



HHS / AMA JOINT SESSION
Opening Remarks



Invited: Regina M. Benjamin, MD, MBA
Surgeon General
Vice Admiral, United States Public Health Service
U.S. Department of Health and Human Services

9:00 – 10:15
Marriott
Salons II & III



HHS / AMA JOINT SESSION
The Future of the PHEMCE



Opening Remarks
Nicole Lurie, MD, MSPH
Rear Admiral, U.S. Public Health Service
Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services



Robin A. Robinson, PhD
Deputy Assistant Secretary, Office of Preparedness and Response
Director, Biomedical Advanced Research and Development Authority
U.S. Department of Health and Human Services



Boris D. Lushniak, MD, MPH
Assistant Surgeon General and Rear Admiral, United States Public Health Service
Assistant Commissioner, Counterterrorism Policy
Office of Counterterrorism and Emerging Threats
Office of the Commissioner, Food and Drug Administration
U.S. Department of Health and Human Services



Daniel M. Sosin, MD, MPH, FACP
Captain, U.S. Public Health Service
Acting Director, Coordinating Office for Terrorism Preparedness and Emergency Response
Centers for Disease Control and Prevention
U.S. Department of Health and Human Services



Carol A. Heilman, PhD
Director, Division of Microbiology and Infectious Disease
National Institute of Allergy and Infectious Disease
National Institutes of Health
U.S. Department of Health and Human Services

10:15 – 10:30

Break in the Marriott Salon Lobby

10:30 – 10:45
Marriott Salon II



Moderator: Carol D. Linden, PhD

Principal Deputy Director
Biomedical Advanced Research and Development Authority
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

Case Study of Anthrax Medical Countermeasure Preparedness and Response

Thomas F. MacKay

Senior Program Analyst
Training, Exercises, and Lessons Learned
Office of Preparedness and Emergency Operations
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

10:45 – 11:45
Marriott Salon II



PANEL: The PHEMCE Process of Developing Medical Countermeasures

Establishing Medical Countermeasure Policy and Requirements

Monique K. Mansoura, PhD

Director, Medical Countermeasure Policy, Planning, and Requirements Division
Biomedical Advanced Research and Development Authority
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

An Integrated Portfolio Approach

Carol D. Linden, PhD

Principal Deputy Director
Biomedical Advanced Research and Development Authority
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

Basic Medical Countermeasure Research

Michael G. Kurilla, MD, PhD

Director, Office of BioDefense Research Affairs
Associate Director for BioDefense Product Development
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases
National Institutes of Health
U.S. Department of Health and Human Services

Supporting Advanced Development

Gerald R. Kovacs, PhD

Director, CBRN Countermeasures
Biomedical Advanced Research and Development Authority
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

11:45 – 11:50
Marriott Salon II



Anthrax Case Study Update #1

11:50 – 12:05
Marriott Salon II



Regulatory Issues for Public Health Emergency Medical Countermeasures

Boris D. Lushniak, MD, MPH

Assistant Surgeon General and Rear Admiral, United States Public Health Service
Assistant Commissioner, Counterterrorism Policy; Office of Counterterrorism and Emerging Threats
Office of the Commissioner, Food and Drug Administration
U.S. Department of Health and Human Services

12:05 – 12:10
Marriott Salon II



Anthrax Case Study Update #2

12:10 – 1:40

Lunch On Your Own

1:40 – 2:15
Marriott Salon II



PANEL: Q & A with the FDA

Moderator: Boris D. Lushniak, MD, MPH

Assistant Surgeon General and Rear Admiral, United States Public Health Service
Assistant Commissioner, Counterterrorism Policy; Office of Counterterrorism and Emerging Threats
Office of the Commissioner, Food and Drug Administration
U.S. Department of Health and Human Services

Sally A. Hojvat, PhD

Director, Division of Microbiology Devices; Office of In-vitro Diagnostic Device Evaluation and Safety
Center for Devices and Radiological Health (CDRH), Food and Drug Administration
U.S. Department of Health and Human Services

Cynthia L. Kelley, MS

Senior Advisor for Counterterrorism and Medical Countermeasures; Office of the Director
Center for Biologics Evaluation and Research (CBER), Food and Drug Administration
U.S. Department of Health and Human Services

Rosemary Roberts, MD

Director, Office of Counterterrorism and Pediatric Drug Development
Center for Drug Evaluation and Research (CDER), Food and Drug Administration
U.S. Department of Health and Human Services

2:15 – 2:20
Marriott Salon II



Anthrax Case Study Update #3

2:20 – 2:50
Marriott Salon II



Moderator: Carol D. Linden, PhD

Principal Deputy Director; Biomedical Advanced Research and Development Authority
Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services

PANEL: Medical Countermeasure Dispensing Issues

Assessing Dispensing Preparedness

Stephanie M. Dulin, MBA

Chief, Program Preparedness Branch; Division of Strategic National Stockpile
Coordinating Office for Terrorism Preparedness and Emergency Response
Centers for Disease Control and Prevention
U.S. Department of Health and Human Services

PREP Act Liability Coverage

Susan Sherman, JD, MHS

Office of the General Counsel
U.S. Department of Health and Human Services

2:50 – 2:55 Marriott Salon II 	Anthrax Case Study Update #4
2:55 – 3:15 Marriott Salon II 	Novel Medical Countermeasure Dispensing Modalities Matthew Minson, MD Senior Medical Officer for Strategic Initiatives Office of Policy, Strategic Planning, and Communications Office of the Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services
3:15 – 3:20 Marriott Salon II 	Anthrax Case Study Update #5
3:20 – 3:35	Break in Marriott Salon Lobby
3:35 – 4:25 Marriott Salon II 	Reports from Break-Out Discussion Sessions
4:25 – 4:35 Marriott Salon II 	Anthrax Case Study Conclusion Thomas F. MacKay Senior Program Analyst; Training, Exercises, and Lessons Learned Office of Preparedness and Emergency Operations Office of the Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services
4:35 – 5:00 Marriott Salon II 	Workshop Summary and Closing Gerald W. Parker, DVM, PhD, MS Principal Deputy Assistant Secretary Office of Preparedness and Response U.S. Department of Health and Human Services
5:00 – 6:00	Reception and Poster Session – Exhibit Hall A



This icon indicates sessions that will be webcast live on December 2 and 3 and archived on www.MedicalCountermeasures.gov in January 2010.

Biomedical Advanced Research and Development Authority (BARDA)

INDUSTRY DAY

Friday, December 4, 2009

In Memory of Our Colleague, Jerome A. Donlon, MD, PhD

<p>VACCINES <i>Washington Room 4</i></p> <p>Moderator: Narayan Iyer, PhD <i>Scientist and Project Officer Acting Chief, Anthrax Vaccines Section Division of CBRN Countermeasures Biomedical Advanced Research and Development Authority Office of the Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services</i></p>	<p>THERAPEUTICS <i>Washington Room 5</i></p> <p>Moderator: Ronald G. Manning, PhD <i>Chief Chemical, Radiological & Nuclear Medical Countermeasures Division of CBRN Countermeasures Biomedical Advanced Research and Development Authority Office of the Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services</i></p>	<p>PLATFORM TECHNOLOGIES <i>Washington Room 6</i></p> <p>Moderator: Dawn Myscofski, PhD, MBA <i>Chief, Smallpox Vaccines and Therapeutics Division of CBRN Countermeasures Biomedical Advanced Research and Development Authority Office of the Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services</i></p>
<p style="text-align: right;">9:00 – 10:08</p> <p>Vaccine Plenary Session: Potency Assay Development</p> <p>Juan L. Arciniega, DSc <i>Laboratory of Methods Development and Quality Control Office of Vaccines Research and Review Center for Biologics Evaluation and Research Food and Drug Administration U.S. Department of Health and Human Services</i></p>	<p style="text-align: right;">9:00 – 9:22</p> <p>ARA 290, a Promising Post-Exposure Radiomitigant for the Gastrointestinal and Hematopoietic Syndromes of the Acute Radiation Syndrome</p> <p>Anthony Cerami Araim Pharmaceuticals, Inc.</p>	<p style="text-align: right;">9:00 – 9:22</p> <p>Rapid and Efficient Immunization Against Pandemic Flu or Agents of Bioterrorism via 3M's Microstructured Transdermal System</p> <p>Kris Hansen 3M Drug Delivery Systems</p>
	<p style="text-align: right;">9:23 – 9:45</p> <p>Rx10X and EDL2000: Two Novel Classes of Radioprotectants and Radiomitigators</p> <p>Gabor Tigyi RxBio, Inc.</p>	<p style="text-align: right;">9:23 – 9:45</p> <p>Human Antibodies for the Treatment of Pandemic Influenza Isolated with a Novel Platform Technology Reveal a Broadly Protective Epitope that is Highly Conserved Among Human and Non-Human Influenza A Viruses</p> <p>Jennifer Mitcham Theraclone Sciences</p>
	<p style="text-align: right;">9:46 – 10:08</p> <p>Mesenchymal Stem Cell-Based Antioxidant Gene Therapy For Radiation Injuries</p> <p>Weiwen Deng Spectrum Health</p>	<p style="text-align: right;">9:46 – 10:08</p> <p>Development of an Aerosol Model for the Assessment of Vaccines and or Antivirals to Smallpox</p> <p>Simon Funnell Health Protection Agency Centre for Emergency Preparedness and Response, UK</p>
<p style="text-align: right;">10:09 – 10:30</p> <p>Development of a Highly Stable Lyophilized rPA Based Anthrax Vaccine</p> <p>Matthew Duchars PharmAthene</p>	<p style="text-align: right;">10:09 – 10:30</p> <p>Cuprimine® and Syprine®, FDA-approved Therapeutics for Wilson Disease, are Promising Candidates to Decorporate the High-Energy Radioisotopes Cobalt-60 and Polonium-210</p> <p>Barry Levinson Aton Pharma, Inc.</p>	<p style="text-align: right;">10:09 – 10:30</p> <p>A Broadly Applicable Stabilisation Technology for Vaccines and Biopharmaceuticals</p> <p>Jefferey Drew Stabilitech, Ltd.</p>

Break 10:30 – 10:50

<p align="center">VACCINES <i>Washington Room 4</i></p> <p align="center">Moderator: Phil Ferro PhD, MS <i>Chief of Portfolio Management Division of CBRN Countermeasures Biomedical Advanced Research and Development Authority Office of the Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services</i></p>	<p align="center">THERAPEUTICS <i>Washington Room 5</i></p> <p align="center">Moderator: Ronald G. Manning, PhD <i>Chief Chemical, Radiological & Nuclear Medical Countermeasures Division of CBRN Countermeasures Biomedical Advanced Research and Development Authority Office of the Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services</i></p>	<p align="center">PLATFORM TECHNOLOGIES <i>Washington Room 6</i></p> <p align="center">Moderator: Brian Dattilo, PhD <i>Project Officer Strategic Science and Technology Division Biomedical Advanced Research and Development Authority Office of the Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services</i></p>
<p align="right">10:50 – 11:12</p> <p align="center">LC16m8, an Attenuated Smallpox Vaccine Will Become an Effective Countermeasure against Bio-terrorism with Smallpox Virus</p> <p align="center">Hiroyuki Yokote Kaketsuken</p>	<p align="right">10:50 – 11:12</p> <p align="center">NanoDTPA Oral Zn-DTPA Capsule and Radiation Countermeasures</p> <p align="center">James Talton Nanotherapeutics, Inc.</p>	<p align="right">10:50 – 11:12</p> <p align="center">DAS181 Fludase® a Late Phase I Host Targeted Antiviral for All Strains of Influenza Including Pandemic H1N1 – a Clinical and Non-Clinical Update</p> <p align="center">David Wurtman NexBio, Inc.</p>
<p align="right">11:13 – 11:35</p> <p align="center">Establishing Industrial Scale Manufacturing for IMVAMUNE®, a Safe Smallpox Vaccine – in Collaboration with BARDA</p> <p align="center">Anders Gram Bavarian Nordic</p>	<p align="right">11:13 – 11:35</p> <p align="center">TransCyte An FDA Approved Treatment and Wound Covering for Thermal Burn Wounds</p> <p align="center">Gary Gentzkow Advanced BioHealing</p>	<p align="right">11:13 – 11:35</p> <p align="center">Leukotriene B4 (LTB4) Stimulates Innate Immune Response in Man; A Novel Approach to Prevent and Treat Influenza Infection</p> <p align="center">Carl-Johan Dalsgaard LTB4 Sweden AB</p>
<p align="right">11:36 – 11:59</p> <p align="center">Advanced Development of a Pan-filovirus Virus-Like Particle (VLP) Vaccine</p> <p align="center">Kelly Warfield Integrated BioTherapeutics, Inc.</p>	<p align="right">11:36 – 11:59</p> <p align="center">Innate Defense Regulators (DRs) Broad-Spectrum Agents with Anti-Inflammatory and Anti-Infective Impact</p> <p align="center">John North Inimex Pharmaceuticals, Inc.</p>	<p align="right">11:36 – 11:59</p> <p align="center">Rapid Host Targeted Protection from H1N1 Pandemic Influenza, SARS, VEE, and Other Respiratory Threats</p> <p align="center">Andres Salazar Oncovir, Inc.</p>

Lunch On Your Own 12:00 – 1:30

<p align="center">VACCINES <i>Washington Room 4</i></p> <p align="center">Moderator: Thomas R. Fuerst, PhD <i>Senior Science and Technology Advisor Strategic Science and Technology Division Biomedical Advanced Research and Development Authority Office of the Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services</i></p>	<p align="center">THERAPEUTICS <i>Washington Room 5</i></p> <p align="center">Moderator: Stephen Morris, PhD <i>Chief, Antitoxins and Therapeutics Division of CBRN Countermeasures Biomedical Advanced Research and Development Authority Office of the Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services</i></p>	<p align="center">PLATFORM TECHNOLOGIES <i>Washington Room 6</i></p> <p align="center">Moderator: Rodney Wallace <i>Chief, CBRN Diagnostics Division of CBRN Countermeasures Biomedical Advanced Research and Development Authority Office of the Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services</i></p>
<p align="right">1:30 – 1:52</p> <p>MP-12, a Live Attenuated Virus Vaccine for the Prevention of Rift Valley Fever</p> <p align="center">George Bettinger University of Texas Medical Branch</p>	<p align="right">1:30 – 1:52</p> <p>Efficacy of Valortim® in the New Zealand White Rabbit Model for Inhalation Anthrax</p> <p align="center">Elizabeth Leffel PharmAthene, Inc.</p>	<p align="right">1:30 – 1:52</p> <p>Advanced Intranasal Delivery Platforms for Liquid and Powder Vaccine Formulations</p> <p align="center">Timothy Sullivan Mystic Pharmaceuticals, Inc.</p>
<p align="right">1:53 – 2:15</p> <p>ISCOMATRIX® Adjuvant Provides Benefits for Both Seasonal and Pandemic Influenza Vaccines</p> <p align="center">Steve Rockman CSL Limited</p>	<p align="right">1:53 – 2:15</p> <p>ACHN-490, a Novel, Broad Spectrum Neoglycoside Antibiotic for the Treatment of Resistant Threat Agents</p> <p align="center">Michael Eichberg Achaogen, Inc.</p>	<p align="right">1:53 – 2:15</p> <p>A Cell-Free Synthetic Biology Platform for the Rapid Engineering and Production of Biological Vaccines and Therapeutics</p> <p align="center">Daniel Gold Sutro Biopharma, Inc.</p>
<p align="right">2:16 – 2:38</p> <p>New Platform for Influenza Vaccines</p> <p align="center">Albert Deisseroth FDA</p>	<p align="right">2:16 – 2:38</p> <p>Advanced Development of Anthim (ETI-204), a Highly-Effective Monoclonal Antibody for Treatment of Inhalation Anthrax: Results of Recent Safety and Efficacy Studies</p> <p align="center">Leslie Casey Elusys Therapeutics, Inc.</p>	<p align="right">2:16 – 2:38</p> <p>A Multidimensional Spectroscopy Platform</p> <p align="center">Luis Garcia-Rubio Claro Scientific, LLC</p>
<p align="right">2:39 – 3:01</p> <p>Rapid, High Capacity Production of Pandemic Influenza Vaccines in <i>E. coli</i></p> <p align="center">Alan Shaw VaxInnate Corp.</p>	<p align="right">2:39 – 3:01</p> <p>The Development of CMX001, a Broad Spectrum Antiviral Drug, for the Prophylaxis and Treatment of Smallpox Infection</p> <p align="center">Gwendolyn Painter Chimerix, Inc.</p>	<p align="right">2:39 – 3:01</p> <p>Commercial Scale Production of Plant Based Proteins</p> <p align="center">Alex Day Kentucky BioProcessing, LLC</p>
<p align="right">3:02 – 3:24</p> <p>Use of the JVRS-100 Adjuvant for Biothreat Vaccines</p> <p align="center">Jeff Fairman Juvaris BioTherapeutics, Inc.</p>	<p align="right">3:02 – 3:24</p> <p>Post-Exposure Administration with ST-246 Prevents the Development of Severe Rabbitpox Disease in NZW Rabbits</p> <p align="center">Peter Silvera Southern Research</p>	<p align="right">3:02 – 3:24</p> <p>Development of a Flexible and Reproducible Aerosol Generation Capability for Use with Select Agents to Allow Medical Countermeasure Testing</p> <p align="center">Miles Carroll Health Protection Agency Centre for Emergency Preparedness and Response, UK</p>

Break 3:30 – 3:50

<p align="center">DIAGNOSTICS <i>Washington Room 4</i></p> <p align="center">Moderator: Rodney Wallace <i>Chief, CBRN Diagnostics Division of CBRN Countermeasures Biomedical Advanced Research and Development Authority Office of the Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services</i></p>	<p align="center">THERAPEUTICS <i>Washington Room 5</i></p> <p align="center">Moderator: Edward Niles, PhD <i>Project Officer, Smallpox Therapeutics Division of CBRN Countermeasures Biomedical Advanced Research and Development Authority Office of the Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services</i></p>	<p align="center">PLATFORM TECHNOLOGIES <i>Washington Room 6</i></p> <p align="center">Moderator: Gary L. Disbrow, PhD <i>Deputy Director Division of CBRN Countermeasures Biomedical Advanced Research and Development Authority Office of the Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services</i></p>
<p align="right">3:50 – 4:12</p> <p>Developing Simple One Step Detectors for Non-Invasive <i>In vitro</i> Screening of Persons Potentially Exposed to Chemical, Biological and Pandemic Influenza Threats</p> <p align="center">Uma Babu Rapid Pathogen Screening, Inc.</p>	<p align="right">3:50 – 4:12</p> <p>A Next-Generation Fluoroquinolone as a Broad-Spectrum Countermeasure for the Defeat of Top Priority Bacterial Threat Agents</p> <p align="center">Michael Eichberg Achaogen, Inc.</p>	<p align="right">3:50 – 4:12</p> <p>CAdVax Vaccine Platform Provides Nonhuman Primates with 100% Protection against Multi-strain Challenges by Ebola, Marburg, Dengue, and Other Infectious Disease Agents</p> <p align="center">John Dong GenPhar, Inc.</p>
<p align="right">4:13 – 4:35</p> <p>Calculator for Estimation of Dose from Radiation Exposure: Versions for the Web and Mobile Devices</p> <p align="center">Judith Bader National Cancer Institute</p>	<p align="right">4:13 – 4:35</p> <p>Recombinant Acetylcholinesterase – Bio Defense Product for Nerve Agents Attack</p> <p align="center">David Aviezer Protalix Biotherapeutics</p>	<p align="right">4:13 – 4:35</p> <p>Use of Operations Management Techniques to Model and Manage Catastrophic Epidemiological Events</p> <p align="center">Mark Abramovich Interdisciplinary Solutions, Inc.</p>
	<p align="right">4:36 – 4:58</p> <p>Phase I Dose Escalating Study of Protexia Pegylated Recombinant Butyrylcholinesterase for Nerve Agent Prophylaxis in Healthy Volunteers</p> <p align="center">Valerie Riddle PharmAthene, Inc.</p>	

